Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 7681 results

  1. Teduglutide for treating short bowel syndrome in babies 4 to 12 months [TS ID 10755]

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

    Awaiting development [GID-TA10774] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Rezafungin for untreated invasive candidiasis TS ID 10768

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]

    Awaiting development [GID-TA11040] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma

    In development [GID-IPG10067] Expected publication date: TBC

    Interventional procedures guidance
    In development

  6. Pernicious anaemia

    Awaiting development [GID-QS10130] Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Abdominal aortic aneurysm

    Awaiting development [GID-QS10035] Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

    Awaiting development [GID-TA10426] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tinnitus

    Awaiting development [GID-QS10091] Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development [GID-TA10446] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Heart valve disease in adults

    Awaiting development [GID-QS10101] Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Diverticular disease

    Awaiting development [GID-QS10086] Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

    In development [GID-TA10326] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Infant, children and young people's experience of health care

    Awaiting development [GID-QS10102] Expected publication date: TBC

    Quality standard
    Awaiting development

  15. Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

    In development [GID-TA10223] Expected publication date: TBC

    Technology appraisal guidance
    In development